ADAR and cancer: In antizyme inhibitor 1 (AZIN1), ADAR1-induced A-to-I editing causes the serine (S) → glycine (G) substitution at residue 367, leading to a cytoplasmic-to-nuclear translocation and “gain-of-function” phenotypes manifested by augmented tumor initiating potential and more aggressive cancer cell behavior [375].